PATH to use Liquidia particle technology for malaria

The PATH Malaria Vaccine Initiative (MVI) will have use of Liquidia Technologies' PRINT particle technology for its research into new, more effective malaria vaccines. The technology helps researchers control the size, shape and chemistry of protein particles used in the malaria vaccine.

"MVI is actively working to identify second generation vaccine approaches with the potential to elicit higher levels of efficacy over a longer period of time; approaches that could target the disease as well as parasite transmission, which will be important in the fight to control and eliminate malaria," said Ashley Birkett, director of Pre- and Early Clinical Research and Development at MVI, in a statement. "The PRINT technology represents an advancement in the controlled delivery of vaccine components, which may enhance efficacy and safety by bringing together multiple technologies necessary to achieve a next-generation malaria vaccine."

- see the Liquidia release

Suggested Articles

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.

As top players race to deliver COVID-19 vaccines, Russia approved a locally developed shot based on skimpy data. Experts called it a political stunt.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan